<DOC>
	<DOCNO>NCT00513643</DOCNO>
	<brief_summary>The metabolic effect three different dos insulin aspart human insulin investigate euglycaemic glucose clamp technique .</brief_summary>
	<brief_title>Metabolic Effect Insulin Aspart Human Insulin Different Doses</brief_title>
	<detailed_description>Double-blind , randomize , 6-period cross-over study 16 healthy subject . Each patient participate 6 euglycemic glucose clamp experiment . The time interval study day 2 28 day . At clamp visit , subject connect Biostator ( MTB Medizintechnik , Ulm , Germany ) receive intravenous human insulin infusion ( rate 0.15 mU/kg/min ) duration experiment prevent rise endogenous insulin secretion . After baseline period 2 h trial drug ( 6 , 12 , 24 U either Insulin Aspart regular human insulin random order ) administer s.c. syringe abdominal wall . Glucose infusion rate ( GIR ) necessary keep blood glucose concentration close clamp level 90 mg/dl ( 5 mmol/l ) administer record Biostator every minute period 12 h post-dosing . Blood sample draw regular interval analysis C-peptide ( depend trial drug administer ) serum insulin serum Insulin Aspart concentration ( measure specific ELISAs ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Inclusion criterion : Signed informed consent obtain trialrelated activity Healthy subject 18 45 year inclusive Considered generally healthy upon completion medical history physical examination Body mass index ( BMI ) &lt; 27 kg/m2 HbA1c &lt; 6,1 % Nonsmoker least three month Females childbearing potential use acceptable method contraception , include tubal ligation , intrauterine device ( IUD ) , oral contraceptive pill barrier method . Participation clinical trial receipt investigational drug within four week prior trial Previous participation trial Clinically significant abnormal haematology biochemistry screen test Any disease requiring use non topical prescription medicine Any serious systemic infectious disease occur four week prior first dose test drug Any intercurrent illness may affect blood glucose Current addiction alcohol substance abuse determined investigator Known suspect allergy insulin component composition trial drug Blood donation &gt; 500 ml within last nine week Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation If female , subject pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>euglycaemic glucose clamp</keyword>
	<keyword>duration action</keyword>
	<keyword>late metabolic activity</keyword>
	<keyword>hypoglycaemia</keyword>
</DOC>